VEGFA and neoplasm: Sorafenib is able to inhibit tumor cell proliferation and angiogenesis by blocking the Ras/Raf/mitogen-activated protein kinase (MAPK) pathway, vascular endothelial growth factor (VEGF) signaling pathway, and platelet-derived growth factor receptor signaling [6].